The firm served as lead counsel for a national research university, asserting a constructive trust theory to protect the university's rights in an antiviral nucleoside analogue active against HIV and HBV, under circumstances in which a pharmaceutical company had filed a U.K. patent application for the drug at issue, without naming inventors. The client's constructive trust claims survived summary judgment and the case settled on confidential terms, under which the client secured the intellectual property of its inventors.
